Table 3.
Percentage of patients with a high (≥50%), low (1–49%) or negative (< 1%) PD-L1 status by treatment type among aNSCLC patients (A) or those with known PD-L1 status (B) receiving 1L CIT alone, combination chemotherapy and CIT, or chemotherapy
| A. | ||||||
| PD-L1a category | KRAS G12C | KRAS WT | ||||
|
1L CIT alone patients (N = 72) |
1L combination chemotherapy + CIT patients (N = 101) |
1L Chemotherapy patients (N = 281) |
1L CIT alone patients (N = 145) |
1L combination chemotherapy + CIT patients (N = 262) |
1L Chemotherapy patients (N = 937) | |
| High (≥50%) | 43 (59.7) | 18 (17.8) | 22 (7.8) | 65 (44.8) | 27 (10.3) | 47 (5.0) |
| Low (1–49%) | 10 (13.9) | 24 (23.8) | 35 (12.5) | 23 (15.9) | 63 (24.0) | 122 (13.0) |
| Negative (< 1%) | 2 (2.8) | 21 (20.8) | 23 (8.2) | 7 (4.8) | 74 (28.2) | 147 (15.7) |
| Missing/unknown | 17 (23.6) | 38 (37.6) | 201 (71.5) | 50 (34.5) | 98 (37.4) | 621 (66.3) |
| B. | ||||||
| PD-L1a category excluding unknown | KRAS G12C | KRAS WT | ||||
|
1L CIT alone patients (N = 55) |
1L combination chemotherapy + CIT patients (N = 63) |
1L chemotherapy patients (N = 80) |
1L CIT alone patients (N = 95) |
1L combination chemotherapy + CIT patients (N = 164) |
1L chemotherapy patients (N = 316) | |
| High (≥50%) | 43 (78.2) | 18 (28.6) | 22 (27.5) | 65 (68.4) | 27 (16.5) | 47 (14.9) |
| Low (1–49%) | 10 (18.2) | 24 (38.1) | 35 (43.8) | 23 (24.2) | 63 (38.4) | 122 (38.6) |
| Negative (< 1%) | 2 (3.6) | 21 (33.3) | 23 (28.8) | 7 (7.4) | 74 (45.1) | 147 (46.5) |
1L first line; aNSCLC advanced non-small cell lung cancer; CIT cancer immunotherapy; PD-L1 programmed death-ligand 1; WT wild type
aPD-L1 high was defined as Tumor Proportion Score ≥ 50%, low 1–49% and negative < 1%